As this website is dedicated to neuropathic pain and the natural treatment of this devasting pain by palmitoylethanolamide, we would like to forward also important news related to neuropathy in general:
With only eight therapies receiving approval from the FDA—all within the past decade—for only four of more than a hundred forms of neuropathy, our neuropathy community desperately needs new and more effective therapies and cures.
And with the across-the-board automatic budget cuts (also known as sequestration cuts)—particularly the 8.2% cuts in the budgets of the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other health-related agencies—as part of the Budget Control Act of 2011, now scheduled to take effect on March 1st, we are at risk of losing momentum on much-needed neuropathy treatments and cures.
That is why we are urging American citicens to write to their elected representatives about the devastating impact of these sequestration cuts to neuropathy research, including:
– Loss of jobs and funding resources for current researchers as well as the next generation of scientists in the neuropathy community across the U.S.;
– Stalling of neuropathy research and much-needed discoveries, new treatments, and cures;
– Impeding approvals of new neuropathy therapies by the FDA;
– Loss of access to neuropathy clinical research trials; and
– Loss of private investments in neuropathy research; among others.
Current funding for these federal research programs expires in March and the fiscal year 2014 budgets are being drafted. Reducing the federal budget deficit by cutting federal medical research budgets will set us back not just in the field of neuropathy, but other diseases as well including cancer, diabetes, heart disease, Alzheimer’s, and mental health disorders, to name a few…which in turn will result in rising health care costs.
We cannot risk losing momentum for neuropathy research. All of us are stakeholders—patients, caregivers, healthcare professionals, patient advocacy organizations, federal agencies, industry, academia, and policymakers—and now, more than ever before, we need to work together to accelerate medical research breakthroughs, not stall them. If you have neuropathy—or care for someone who does—please act now!